HDAC inhibitors target epigenetic modifications by inhibiting the deacetylation of histones and non-histone proteins, leading to the reactivation of tumor suppressor genes, disruption of MM cell proliferation, and induction of apoptosis [107]. Here, H2BC12L is linked to Miyoshi myopathy.